Navigation Links
Cell Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes

SEATTLE, June 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the Russell 3000®, Russell 2000® and Russell Global Indexes posted by Russell Investments on June 27, 2011 at  

Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Membership in the Russell Global Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in institutional assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell Indexes is available at

About Russell

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has about $161 billion in assets under management as of March 31, 2011, and serves individual, institutional and advisor clients in more than 35 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of our securities. Specifically, the risks and uncertainties include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and CTI in particular, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing products, CTI's ability to continue to raise capital as needed to fund its operations, the impact of CTI's inclusion in the Russell 3000® Index, Russell 2000® Index and/or the Russell Global Index or a determination by Russell Investments not to include CTI in the Russell 3000® Index, Russell 2000® Index and/or the Russell Global Index and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q, and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200

Investors Contact:

Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
(Date:11/24/2015)... USA , Inc. (OTCQB: WCUI), today provided an update on ... targeted dermatology markets in Boston , Philadelphia ... Carolina . This follows earlier shipments to the Miami ... and New York dermatology markets. ... on October 1, 2015 will be realized in the pending quarter, ending ...
(Date:11/24/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that it will ... December. Date: Wednesday, December 2, 2015 Time: 2:30 ... --> Date: Wednesday, December 2, 2015 Time: 2:30 ... --> Piper Jaffray 27th Annual Healthcare Conference Date: ... New York, New York Date: Tuesday, ...
(Date:11/24/2015)... and BOSTON , November 24, 2015 /PRNewswire/ ... Ltd., a clinical stage company engaged in the commercial development ... today announced the appointment of Richard A. "Dick" Sandberg to ... , -->      (Logo: , ... a principal role in founding and building a number of ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... The ... to support their local poison centers through donations on Tuesday, Dec. 1, 2015. ... it “a day that inspires people to collaborate in improving their local communities ...
(Date:11/24/2015)... ... ... Cold Shoulder , LLC launched their Pro Vest, the latest version of their widely ... $20,000 in under 10 hours. , The campaign, which will continue to ... to the market. , The PRO Vest provides consumers with a less expensive, one-size fits ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
(Date:11/24/2015)... ... 2015 , ... All her life, Don Peck’s mother wondered if she was a descendant of ... been. After a 25-year search for information, Don and his aunt discovered that she ... name. Turns out, it was Don’s father who was descended from not one, but ...
(Date:11/24/2015)... ... November 24, 2015 , ... “I am so thrilled, as a newbie here, to ... she had won a $7,500 School Lounge Makeover® from California Casualty . Stephanie is ... the staff has a much longer tenure. , “This is such an amazing school and ...
Breaking Medicine News(10 mins):